Form 4: Tenaya Therapeutics Grants Equity to SVP Finance

Tenaya Therapeutics, Inc. granted 29,250 restricted stock units and options for 175,500 shares to SVP of Finance, Tomohiro Higa, as part of its 2021 Equity Incentive Plan.

Summary

• Tomohiro Higa, SVP of Finance at Tenaya Therapeutics, Inc. (TNYA), was granted 29,250 shares of common stock in the form of restricted stock units (RSUs) on February 3, 2026.
• These RSUs will vest as to 1/8th of the total number of shares on August 15, 2026, and 1/8th every six months thereafter until fully vested.
• Additionally, Higa was granted stock options for 175,500 shares with an exercise price of $0.915 on February 3, 2026.
• The stock options will vest as to 1/48th of the total shares on the one-month anniversary of the transaction date and 1/48th each monthly anniversary thereafter until fully vested, with an expiration date of February 2, 2036.
• Following these transactions, Higa beneficially owns 123,221 shares of common stock (including 79,720 previously granted RSUs) and 175,500 derivative securities (stock options).
• Both grants were made pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While routine, it signifies continued executive alignment with shareholder interests and a commitment to long-term performance, without indicating any immediate operational or financial shifts.

Positives

• The equity grants align the financial interests of a key executive, Tomohiro Higa (SVP, Finance), with those of the shareholders, incentivizing long-term company performance.
• The grants are part of a structured 2021 Equity Incentive Plan, indicating a formal and transparent approach to executive compensation.

Negatives

• The future vesting and potential exercise of these restricted stock units and stock options will result in a minor dilution of existing shareholder equity.

Risks

• The value of the granted equity compensation is subject to the future market performance of Tenaya Therapeutics, Inc.'s common stock, which could fluctuate.
• Future dilution from the exercise of options and vesting of RSUs could slightly impact earnings per share for existing shareholders.

Future Outlook

The grants of restricted stock units and stock options include specific vesting schedules extending into the future, indicating a long-term commitment for the SVP of Finance, Tomohiro Higa, to the company's performance and growth. The stock options have an expiration date of February 2, 2036.

Industry Context

StockSavvy.ai notes that the grant of equity compensation, including restricted stock units and stock options, to senior executives is a standard practice across the biotechnology and pharmaceutical industries. This approach is widely used to attract, retain, and incentivize key talent by aligning their financial success with the long-term performance of the company's stock. Companies like Moderna, BioNTech, and Regeneron frequently utilize similar equity-based compensation structures for their leadership teams.

Comparison to Industry Standards

• The use of both restricted stock units (RSUs) and stock options for executive compensation is a common practice in the biotechnology sector, similar to compensation packages observed at companies such as Sarepta Therapeutics or Alnylam Pharmaceuticals.
• The vesting schedules, with RSUs vesting over approximately four years (1/8th every six months) and options vesting monthly over four years (1/48th monthly), are typical for executive retention and performance incentives in the industry, comparable to those seen in grants at companies like Vertex Pharmaceuticals or Gilead Sciences.
• The exercise price of $0.915 for the options, while specific to Tenaya's stock price at the time of grant, is a standard mechanism for 'at-the-money' or 'in-the-money' options, designed to provide value as the stock price appreciates, a common feature in executive option grants across the S&P 500.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting and exercise of equity, but also benefit from increased executive alignment with long-term company performance.
• Employees (specifically Tomohiro Higa): Receives significant equity compensation, incentivizing continued dedication and performance.

Next Steps

• The restricted stock units will begin vesting on August 15, 2026, with subsequent vesting every six months thereafter until fully vested.
• The stock options will begin vesting on the one-month anniversary of the transaction date (March 3, 2026), with subsequent monthly vesting until fully vested.

Key Dates

Recommendation

This Form 4 filing reports routine executive compensation in the form of equity grants. It does not contain information that would fundamentally alter the investment thesis for Tenaya Therapeutics, Inc. While it signals executive alignment, it is not a catalyst for a significant change in stock valuation or a strong buy/sell recommendation. A seasoned investor would likely maintain their current position based solely on this information.

Keywords

Tenaya Therapeutics, TNYA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Tomohiro Higa, SVP Finance, 2021 Equity Incentive Plan